Ovarian Cancer New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer Ulas D. Bayraktar, MD 2023-06-24
Soft Tissue Sarcoma New Protocol: Nivolumab and Trabectedin in Advanced Soft Tissue Sarcoma Ulas D. Bayraktar, MD 2023-06-24
Hepatocellular Carcinoma New Indication: Adjuvant Atezolizumab – Bevacizumab in HCC Ulas D. Bayraktar, MD 2023-06-24
GastroEsophageal Cancer New Protocol: Trastuzumab, Ramucirumab, and PACLitaxel for her2-Positive Advanced Gastroesophageal Cancer Ulas D. Bayraktar, MD 2023-06-24
Non-Small Cell Lung Cancer New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC Ulas D. Bayraktar, MD 2023-06-24
Biliary Tract Cancer New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer Ulas D. Bayraktar, MD 2023-06-24
Renal Cell Carcinoma New Protocol: Belzutifan and Cabozantinib for Advanced RCC Ulas D. Bayraktar, MD 2023-06-24
